Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report) shares passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $1.21 and traded as high as $1.79. Cortexyme shares last traded at $1.66, with a volume of 185,014 shares changing hands.
Cortexyme Stock Performance
The stock has a market capitalization of $50.05 million, a PE ratio of -0.56 and a beta of 1.40. The firm has a 50 day moving average of $1.88 and a 200-day moving average of $1.21.
Cortexyme Company Profile
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
Featured Stories
- Five stocks we like better than Cortexyme
- Breakout Stocks: What They Are and How to Identify Them
- Oracle Announces Game-Changing News for the AI Industry
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Netflix Adds 19 Million Subscribers, Growth Is Far From Over
- Why Are Stock Sectors Important to Successful Investing?
- Tempus AI: A Game-Changer in AI-Powered Healthcare
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
